Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22080126 | 0.87 | CTSL (0.51) | CTSLCTSBCTSSALDH1A1GAA | |
| SCHEMBL19900624 | 0.81 | CTSS (0.50) | CTSLCTSBCTSSALDH1A1GAA | |
| SCHEMBL29332331 | 0.80 | CTSL (0.46) | CTSLCTSBCTSSALDH1A1GAA | |
| SCHEMBL19920812 | 0.80 | LMNA (0.44) | CTSLCTSBCTSSALDH1A1GAA | |
| SCHEMBL28293240 | 0.79 | ALDH1A1 (0.49) | CTSLCTSBCTSSALDH1A1GAA | |
| SCHEMBL29857191 | 0.78 | CTSS (0.48) | CTSLCTSBCTSSALDH1A1GAA | |
| SCHEMBL19920814 | 0.78 | LMNA (0.43) | CTSLCTSBCTSSALDH1A1GAA | |
| SCHEMBL19900776 | 0.77 | CTSB (0.50) | CTSLCTSBCTSSALDH1A1GAA | |
| SCHEMBL10556366 | 0.77 | CTSL (0.52) | CTSLCTSBCTSSALDH1A1GAA | |
| SCHEMBL19920827 | 0.76 | CTSB (0.49) | CTSLCTSBCTSSALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12161625-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| EP-3922634-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2023-10-25 | — | — | EP | disclosed |
| EP-3922634-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2023-10-25 | — | — | EP | disclosed |
| US-20230270719-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230270719-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230270719-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| EP-3759109-B1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES INC (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2023-05-11 | — | — | US | disclosed |
| EP-3759109-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES, INC. (US) | 2021-01-06 | — | — | EP | disclosed |
| US-10874640-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-12-29 | — | — | US | disclosed |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2020-11-17 | — | — | US | disclosed |
| US-20200061024-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2020-02-27 | — | — | US | disclosed |
| US-20190292187-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2019-09-26 | — | — | US | disclosed |
| WO-2019165374-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AS HBV REPLICATION INHIBITORS | GILEAD SCIENCES, INC. (US) | 2019-08-29 | — | — | WO | disclosed |
| US-10328053-B2 | Substituted pyrrolizine compounds and uses thereof | GILEAD SCIENCES, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180161307-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2018-06-14 | — | — | US | disclosed |
| US-20180161307-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. | 2018-06-14 | — | — | US | disclosed |
| WO-2018039531-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2018-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200061024-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
| US-12161625-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
| US-10836769-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
| US-10328053-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
| US-20230148157-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
| US-20230270719-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
| US-10874640-B2 | Substituted pyrrolizine compounds and uses thereof | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
| US-20190292187-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
| US-20180161307-A1 | SUBSTITUTED PYRROLIZINE COMPOUNDS AND USES THEREOF | HMBS, DHFR, HCCS | CTSL 1324/4885CTSB 2201/4885CTSS 3150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.